Recombinant Antibodies

Recombinant Antibodies are novel antibodies produced in vitro using genetic engineering techniques. Antibody genes are cloned into expression vectors and expressed in culture systems such as mammalian cells, yeast, or bacteria, completely eliminating reliance on traditional animal immunization and hybridoma technology.
This technical approach offers multiple core advantages:
Defined sequences: complete genetic information enables precise editing and optimization;
Animal-free production: avoids ethical concerns and reduces the risk of pathogen contamination;
Engineerability: facilitates targeted design such as humanization, fragmentation, and conjugation modifications;
Rapid generation: bypasses tedious hybridoma screening, significantly shortening the production cycle.
Compared with traditional antibodies, recombinant antibodies outperform hybridoma-derived monoclonal antibodies and polyclonal antibodies in sequence transparency, degree of humanization (designable as 100% human), batch stability, and engineering flexibility. Despite relatively higher costs, they have become the preferred technical platform for therapeutic drug development, diagnostic reagent production, and customized research tools, driving antibody engineering into a new era of precise design.